신테카바이오

226330KOSDAQ소프트웨어 개발 및 공급업

44.2 / 100

Reference Date: 2026-04-13

Financial Score13.0 / 40

News Sentiment17.2 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Slightly down 3.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Synetica Bio is a biotech venture company established in 2009, specializing in AI-driven drug discovery platforms and genomics big data solutions. Its core services include DeepMatcher® hit screening, personalized neoantigen identification (NEO-ARS®), and genomic precision medicine (NGS-ARS®), with revenue generated through both platform services and in-house drug pipelines. The company leverages its supercomputing infrastructure and partnerships to maintain a competitive edge in the industry.

Number of Employees

49people

Average Salary

61.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 14.434.0Point

PBR

2.44Industry Average 1.281.0Point

1.9x industry avg (risky)

ROE

-61.27Industry Average 1.360.0Point

Well below industry avg

Debt Ratio

7.90Industry Average 7.934.0Point

In line with industry avg

Trend 2023~20254.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲1367.3% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -41.1% (declining, 3yr)

Detailed News Sentiment

4 totalPositive 3Neutral 0Negative 0Average Sentiment Score 75

Positive
신테카바이오, ‘2026년 산학연 Collabo R&D’ 2단계 선정…...
신테카바이오는 AI 신약개발 플랫폼 '딥매처'를 활용한 건선 치료 유효물질 확보 성과를 기반으로 '2026년 산학연 Collabo R&D' 사업 2단계에 최종 선정되었다.
Positive
신테카바이오, AI 독성 예측 기반 발암 위험 평가 가능성 제시
신테카바이오는 AI 기반 분자 언어모델을 활용해 화학물질의 경구 독성을 예측한 연구 논문이 국제 SCI 학술지 'Frontiers in Oncology'에 게재되었다.
Positive
신테카바이오 "분자언어모델 기반 독성예측, 발암위험평가에 활용가능.....
신테카바이오의 분자 언어모델 기반 독성 예측 연구는 발암 위험 평가에 활용 가능하며, 기존 평가 방식의 시간 및 비용 소요를 보완할 것으로 기대된다.

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 3,200Won52-week high 6,91152-week low 2,895

1-month return2.0Point

1m -3.32% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral[기재정정]투자판단관련주요경영사항 (AbARS™플랫폼으로 발굴한 항암 및 면역질환 항체 후보물질 기술이전)2026-04-10
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-04-07
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-27
Neutral정기주주총회결과2026-03-27
Neutral사업보고서 (2025.12)2026-03-19